*New York University Grossman School of Medicine, New York, NY;

†Department of Medicine, NYU Langone Long Island Hospital, Mineola, NY;

‡The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY;

§Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

¶Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

║Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

**Heart and Vascular Center, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and

††Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, NY.

Correspondence: Michael S. Garshick, MD, MS, 435 East 30th St, 7th Floor NYU Langone Health, New York, NY 10016 (e-mail: [email protected]).

J. T. Shah is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445. M. S. Garshick is supported in part by a K23HL152013 and unrestricted Pfizer Research Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

A. N. Femia reports consultant fees for Timber Pharmaceuticals, Guidepoint, Octagon Therapeutics, Anthenum, and First Thought. K. I. Lo Sicco is a current investigator for Pfizer and previous investigator for Regen Lab; she is a consultant for Pfizer and Aquis. J. F. Merola is a consultant and/or investigator for Amgen, Boehringer Inhelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. B. Weber is on the scientific advisory board for Horizon (ended), Novo Nordisk, Esperion, and Kiniksa. M. S. Garshick reports consultant fees for AbbVie and Horizon Therapeutics. No other conflicts of interest were reported.

B. Weber and M. S. Garshick have contributed equally